Skip to main content

Advertisement

SpringerLink
Log in

Analysis of Differential BRAFV600E Mutational Status in High Aggressive Papillary Thyroid Microcarcinoma

  • Head and Neck Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Papillary thyroid cancers often occur as microcarcinoma. Some papillary thyroid microcarcinoma (PTMC) have been considered to be high aggressive according to advanced disease stages, extrathyroidal extension, and severe cervical lymph node metastasis. Although several factors are thought to predict the occurrence of aggressiveness from PTMCs, the origin of aggressiveness has been rarely studied. To answer this question, the correlation between BRAFV600E mutation and high aggressive PTMCs was investigated. The clinicopathological characteristic of totally 64 cases of PTMCs was investigated and the BRAFV600E mutational status of them was identified. BRAFV600E mutation was exclusively detected in PTMCs (37.5%). The data provided no correlation between the occurrence of BRAFV600E mutations and clinicopathological parameters, such as sex, age, and tumor-like lesions combination. The prevalence of BRAFV600E mutation of PTMCs with high aggressiveness (advanced disease stages, extrathyroidal extension, and nodal metastasis) was significantly higher (p < 0.05) than that of PTMCs without aggressive behavior. The BRAFV600E mutated PTMCs exhibited signs of higher aggressiveness than PTMCs without the mutation. BRAFV600E mutation may be a marker of high aggressiveness in PTMCs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab. 2003;88:4393–7.

    Article  PubMed  CAS  Google Scholar 

  2. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2003;88:5399–404.

    Article  PubMed  CAS  Google Scholar 

  3. Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res. 2003;63:4561–7.

    PubMed  CAS  Google Scholar 

  4. Kim KH, Kang DW, Kim SH, Seong IO, Kang DY. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J. 2004;45:818–21.

    PubMed  CAS  Google Scholar 

  5. Puxeddu E, Moretti S, Elisei R, Romei C, Pascucci R, Martinelli M, et al. BRAF (V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab. 2004;89:2414–20.

    Article  PubMed  CAS  Google Scholar 

  6. Leenhardt L, Grosclaude P, Chérié-Challine L for the Members of the Thyroid Cancer Committee. Increased incidence of thyroid carcinoma in France: a true epidemic or thyroid nodule management effects? Report from the French thyroid cancer committee. Thyroid. 2004;14:1056–60.

    Google Scholar 

  7. Chow SM, Law SCK, Chan JKC, Au SK, Yau S, Lau WH. Papillary microcarcinoma of the thyroid-prognostic significance of lymph node metastasis and multifocality. Cancer. 2003;98:31–40.

    Article  PubMed  Google Scholar 

  8. Yamashita H, Noguchi S, Murakami N, Toda M, Uchino S, Watanabe S, et al. Extracapsular invasion of lymph node metastasis. A good indicator of disease recurrence and poor prognosis in patients with thyroid microcarcinoma. Cancer. 1999;86:842–84.

    Article  PubMed  CAS  Google Scholar 

  9. Roti E, Rossi R, Trasforini G, Bertelli F, Ambrosio MR, Busutti L, et al. Clinical and histological characteristics of papillary thyroid microcarcinoma: results of a retrospective study in 243 patients. J Clin Endocrinol Metab. 2006;91:2171–8.

    Article  PubMed  CAS  Google Scholar 

  10. Wada N, Duh QY, Sugino K, Iwasaki H, Kameyama K, Mimura T, et al. Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence, and optimal strategy for neck dissection. Ann Surg. 2003;237:399–407.

    Article  PubMed  Google Scholar 

  11. Pelizzo MR, Boschin IM, Toniato A, Pagetta C, Piotto A, Bernante P, et al. Natural history, diagnosis, treatment and outcome of papillary thyroid microcarcinoma (PTMC): a mono-institutional 12-year experience. Nucl Med Commun. 2004;25:547–52.

    Article  PubMed  Google Scholar 

  12. Pellegriti G, Scollo C, Lumera G, Regalbuto C, Vigneri R, Belfiore A 2004 Clinical behavior and outcome of papillary thyroid cancers smaller than 1.5 cm in diameter: study of 299 cases. J Clin Endocrinol Metab. 89:3713–20.

    Article  PubMed  CAS  Google Scholar 

  13. Fukushima T, Suzuki S, Mashiko M, Ohtake T, Endo Y, Takebayashi Y, et al. BRAF mutations in papillary carcinomas of the thyroid. Oncogene. 2003;22:6455–7.

    Article  PubMed  CAS  Google Scholar 

  14. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst. 2003;95:625–7.

    Article  PubMed  CAS  Google Scholar 

  15. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC–RAS–BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003;63:1454–7.

    PubMed  CAS  Google Scholar 

  16. Salvatore G, Giannini R, Faviana P, Caleo A, Migliaccio I, Fagin JA, et al. Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2004;89:5175–80.

    Article  PubMed  CAS  Google Scholar 

  17. Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene. 2003;22:4578–80.

    Article  PubMed  CAS  Google Scholar 

  18. Mitsutake N, Knauf JA, Mitsutake S, Mesa C Jr, Zhang L, Fagin JA. Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells. Cancer Res. 2005;65:2465–73.

    Article  PubMed  CAS  Google Scholar 

  19. Fugazzola L, Mannavola D, Cirello V, Vannucchi G, Muzza M, Vicentini L, et al. BRAF mutations in an Italian cohort of thyroid cancers. Clin Endocrinol. 2004;61:239–43.

    Article  CAS  Google Scholar 

  20. Sedliarou I, Saenko V, Lantsov D, Rogounovitch T, Namba H, Abrosimov A, et al. The BRAFT1796A transversion is a prevalent mutational event in human thyroid microcarcinoma. Int J Oncol. 2004;25:1729–35.

    PubMed  CAS  Google Scholar 

  21. Vasko V, Hu S, Wu G, Xing JC, Larin A, Savchenko V, et al. High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. J Clin Endocrinol Metab. 2005;90:5265–9.

    Article  PubMed  CAS  Google Scholar 

  22. Reinhoff WF Jr. Lymphatic vessels of thyroid gland in dog and man. Arch Surg. 1931;23:783–804.

    Google Scholar 

  23. Park SY, Park YJ, Lee YJ, Lee HS, Choi SH, Choe G, et al. Analysis of differential BRAFV600E mutational status in multifocal papillary thyroid carcinoma. Cancer. 2006;107:1831–8.

    Article  PubMed  CAS  Google Scholar 

  24. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer. 2005;12:245–62.

    Article  PubMed  CAS  Google Scholar 

  25. Hay ID, Grant CS, van Heerden JA, Goellner JR, Ebersold JR, Bergstralh EJ. Papillary thyroid microcarcinoma: a study of 535 cases observed in a 50-year period. Surgery. 1992;112:1139–47.

    PubMed  CAS  Google Scholar 

  26. Roh JL, Kim JM, Park CI. Central cervical nodal metastasis from papillary thyroid microcarcinoma: pattern and factors predictive of nodal metastasis. Ann Surg Oncol. 2008;15:2482–6.

    Article  PubMed  Google Scholar 

  27. Lin JD, Kuo SF, Chao TC, Hsueh C. Incidental and nonincidental papillary thyroid microcarcinoma. Ann Surg Oncol. 2008;15:2287–92.

    Article  PubMed  Google Scholar 

  28. Leboulleux S, Rubino C, Baudin E, Caillou B, Hartl DM, Bidart JM, et al. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab. 2005;90:5723–9.

    Article  PubMed  CAS  Google Scholar 

  29. Mazzaferri EL, Young RL. Papillary thyroid carcinoma: a 10 year follow-up. Report of the impact of therapy in 576 patients. Am J Med. 1981;70:511–8.

    Article  PubMed  CAS  Google Scholar 

  30. Jukkola A, Bloigu R, Ebeling T, Salmela P, Blanco G. Prognostic factors in differentiated thyroid carcinomas and their implications for current staging classifications. Endocr Relat Cancer. 2004;11:571–9.

    Article  PubMed  Google Scholar 

  31. Trovisco V, Vieira de Castro I, Soares P, Máximo V, Silva P, Magalhães J, et al. BRAF mutations are associated with histologic types of papillary thyroid carcinoma. J Pathol. 2004;202:247–51.

    Article  PubMed  CAS  Google Scholar 

  32. Trovisco V, Soares P, Preto A, Vieira de Castro I, Lima J, Castro P, et al. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients’ age but not with tumour aggressiveness. Virchows Arch. 2005;446:589–95.

    Article  PubMed  CAS  Google Scholar 

  33. Knauf JA, Ma X, Smith EP, et al. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res. 2005;65:4238–45.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors thank Drs. Baocun Sun for providing material, and Lili Yang and Feng Fei for grant support to Xiaolong Lee, Ming Gao, Yifeng Ji, Yang Yu, Ying Feng, Yigong Li, Yan Zhang, Wenyuan Cheng, and Wenchuan Zhao.

Author information

Authors and Affiliations

  1. Department of Thyroid & Neck, Tianjin Medical University Cancer Hospital, Tianjin, China

    Xiaolong Lee PhD, Ming Gao MD, Yifeng Ji MS, Yang Yu PhD, Ying Feng MS, Yigong Li MD, Yan Zhang BS, Wenyuan Cheng BS & Wenchuan Zhao MD

Authors
  1. Xiaolong Lee PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ming Gao MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yifeng Ji MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yang Yu PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ying Feng MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yigong Li MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yan Zhang BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Wenyuan Cheng BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Wenchuan Zhao MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ming Gao MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lee, X., Gao, M., Ji, Y. et al. Analysis of Differential BRAFV600E Mutational Status in High Aggressive Papillary Thyroid Microcarcinoma. Ann Surg Oncol 16, 240–245 (2009). https://doi.org/10.1245/s10434-008-0233-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-008-0233-3

Keywords

Search

Navigation